Identification of conditionally essential genes for Streptococcus suis infection in pigs

Streptococcus suis is a Gram-positive bacterium and zoonotic pathogen that causes meningitis and sepsis in pigs and humans. The aim of this study was to identify genes required for S. suis infection. We created Tn-Seq libraries in a virulent S. suis strain 10, which was used to inoculate pigs in an intrathecal experimental infection. Comparative analysis of the relative abundance of mutants recovered from different sites of infection (blood, cerebrospinal fluid, and meninges of the brain) identified 361 conditionally essential genes, i.e. required for infection, which is about 18% of the genome. The conditionally essential genes were primarily involved in metabolic and transport processes, regulation, ribosomal structure and biogenesis, transcription, and cell wall membrane and envelope biogenesis, stress defenses, and immune evasion. Directed mutants were created in a set of 10 genes of different genetic ontologies and their role was determined in ex vivo models. Mutants showed different levels of sensitivity to survival in whole blood, serum, cerebrospinal fluid, thermic shock, and stress conditions, as compared to the wild type. Additionally, the role of three selected mutants was validated in co-infection experiments in which pigs were infected with both wild type and isogenic mutant strains. The genetic determinants of infection identified in this work contribute to novel insights in S. suis pathogenesis and could serve as targets for novel vaccines or antimicrobial drugs

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

AIM: To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis. METHODS: Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis C genotype 1, treatment-nai¨ve (TN) or treatment-experienced (TE), who underwent triple therapy with the first generation NS3/4A protease inhibitors, boceprevir (BOC) and telaprevir (TVR), in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow up. RESULTS: One thousand and fifty seven patients were included, 405 (38%) were treated with BOC and 652 (62%) with TVR. Of this total, 30% (n = 319) were TN and the remaining were TE: 28% (n = 298) relapsers, 12% (n = 123) partial responders (PR), 25% (n = 260) null-responders (NR) and for 5% (n = 57) with prior response unknown. The rate of sustained virologic response (SVR) by intention-to-treatment (ITT) was greater in those treated with TVR (65%) than in those treated with BOC (52%) (P < 0.0001), whereas by modified intention-to-treatment (mITT) no were found significant differences. By degree of fibrosis, 56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients, both TN and TE. In the analysis by groups, the TN patients treated with TVR by ITT showed a higher SVR (P = 0.005). However, by mITT there were no significant differences between BOC and TVR. In the multivariate analysis by mITT, the significant SVR factors were relapsers, IL28B CC and non-F4; the type of treatment (BOC or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients, treated with BOC (46%) or with TVR (45%). 28% of the patients interrupted the treatment, mainly by non-viral response (51%): this outcome was more frequent in the TE than in the TN patients (57% vs 40%, P = 0.01). With respect to severe haematological disorders, neutropaenia was more likely to affect the patients treated with BOC (33% vs 20%, P = 0.0001), and thrombocytopaenia and anaemia, the F4 patients (P = 0.000, P = 0.025, respectively). CONCLUSION: In a real clinical practice setting with a high proportion of patients with advanced fibrosis, effectiveness of first-generation PIs was high except for NR patients, with similar SVR rates being achieved by BOC and TVR

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize the resistance profile of a large cohort of patients failing DAA-based treatments, and investigate the relationship between HCV subtype and failure, as an aid to optimizing management of these patients. A new, standardized HCV-RAS testing protocol based on deep sequencing was designed and applied to 220 previously subtyped samples from patients failing DAA treatment, collected in 39 Spanish hospitals. The majority had received DAA-based interferon (IFN) a-free regimens; 79% had failed sofosbuvir-containing therapy. Genomic regions encoding the nonstructural protein (NS) 3, NS5A, and NS5B (DAA target regions) were analyzed using subtype-specific primers. Viral subtype distribution was as follows: genotype (G) 1, 62.7%; G3a, 21.4%; G4d, 12.3%; G2, 1.8%; and mixed infections 1.8%. Overall, 88.6% of patients carried at least 1 RAS, and 19% carried RAS at frequencies below 20% in the mutant spectrum. There were no differences in RAS selection between treatments with and without ribavirin. Regardless of the treatment received, each HCV subtype showed specific types of RAS. Of note, no RAS were detected in the target proteins of 18.6% of patients failing treatment, and 30.4% of patients had RAS in proteins that were not targets of the inhibitors they received. HCV patients failing DAA therapy showed a high diversity of RAS. Ribavirin use did not influence the type or number of RAS at failure. The subtype-specific pattern of RAS emergence underscores the importance of accurate HCV subtyping. The frequency of “extra-target” RAS suggests the need for RAS screening in all three DAA target regions

Single crystal growth of lead (II) n-octa-, n-nona- and n-decanoate

Single crystals of lead (II) n-octa (Pb(C8)2), n-nona (Pb(C9)2), and n-decanoate (Pb(C10)2) have been obtained by using a silica gel technique. These crystals have been identified by polarizing light microscopy, X-ray diffraction, Raman spectroscopy, and scanning electron microscopy. The crystals show polyhedral morphology bounded by flat (001) faces and non-flat striated faces. Cleavage lines can be observed in the (001) faces. This cleavage can be related with the bilayer structure of these compounds. Two kinds of crystals with different internal cleavage angle have been found in Pb(C9)2 and Pb(C10)2. The value of this angle is 90° in one of them and 120° in the other one. This fact can be explained by taking into account the polymorphism and polytypism in the lead (II) alkanoates series

Short chain lead (II) alkanoates as ionic liquids and glass formers: A d.s.c., X-ray diffraction and FTIR spectroscopy study

Three members of the lead (II) n-alkanoates (from etanoate to n-butanoate) have been synthesized, purified and studied by d.s.c., Xray diffraction, and FTIR spectroscopy. Lead (II) acetate, propanoate, and butanoate present only a melting transition at T = (452.6, 398.2, and 346.5) K, with DfH = (16.0, 13.1, and 15.6) kJ Æ mol1, and DfS = (35.3, 32.8, and 45.1) J Æ mol1 Æ K1, respectively. These temperature data correct to a great extent the historical values reported in the literature. These three members readily quench into a glass state. Their corresponding Tg values are (314.4, 289.0, and 274.9) K, respectively, measured by d.s.c. at a heating rate of 5 K Æ min-1

Bisphenol a exposure and kidney diseases : Systematic review, meta-analysis and nhanes 03-16 study

Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER); Comunidad Autónoma de Madrid (B2017-BMD-3686).Bisphenol A (BPA) is a compound that is especially widespread in most commonly used objects due to its multiple uses in the plastic industry. However, several data support the need to restrict its use. In recent years, new implications of BPA on the renal system have been discovered, which denotes the need to expand studies in patients. To this end, a systematic review and a meta-analysis was performed to explore existing literature that examines the BPA-kidney disease paradigm and to determine what and how future studies will need to be carried out. Our systematic review revealed that only few relevant publications have focused on the problem. However, the subsequent meta-analysis revealed that high blood concentrations of BPA could be a factor in developing kidney disease, at least in people with previous pathologies such as diabetes or hypertension. Furthermore, BPA could also represent a risk factor in healthy people whose urinary excretion is higher. Finally, the data analyzed from the NHANES 03-16 cohort provided new evidence on the possible involvement of BPA in kidney disease. Therefore, our results underline the need to carry out a thorough and methodologically homogeneous study, delving into the relationship between urinary and blood BPA, glomerular filtration rate, and urine albumin-to-creatinine ratio, preferably in population groups at risk, and subsequently in the general population, to solve this relevant conundrum with critical potential implications in Public Health

A novel rotator glass in lead (II) pentanoate: Calorimetric and spectroscopic study

Lead(II) pentanoate was studied by DSC, XRD, and FTIR and solid state CP/MAS-NMR spectroscopies. A transition from the crystal to the intermediate phase, at Tss = 328.2 ± 0.6 K, with δ H = 8.8 ±0.1 kJ* mol-1, and a melting at Tf = 355.6 ± 0.3 K, with δfH = 12.6 ± 0.1 kJ-mor -1, were observed on first heating. The thermal and structural behavior of the lead(II) pentanoate shows as a link between those of the shorter and longer members of the previously studied lead(II) alkanoate series. The optical microscopy and FTIR vs temperature studies show structural changes from the crystal to the intermediate phase and its solid state nature. Moreover, X-ray diffraction and C-13 and Pb-207 CP/MAS-NMR studies confirm the rotator nature of the intermediate phase in this compound. Two different glass states, one from the isotropic liquid and another from the rotator phase, were obtained by quenching at high and low rates, respectively. The glass transition temperatures (measured at 5 K.min-1) were 322.9 and 275.7K, respectively.Ministerio de Educación y CienciaDepto. de Mineralogía y PetrologíaFac. de Ciencias GeológicasTRUEpu